Extended Data Fig. 8: Peripheral blood and tumor samples from 1,344 patients treated with nivolumab or nivolumab plus ipilimumab in 4 phase 3 clinical trials included in the analyses. | Nature Medicine

Extended Data Fig. 8: Peripheral blood and tumor samples from 1,344 patients treated with nivolumab or nivolumab plus ipilimumab in 4 phase 3 clinical trials included in the analyses.

From: Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors

Extended Data Fig. 8

Summary of 4 phase 3 clinical trials (CheckMate 067, CheckMate 017, CheckMate 057, CheckMate 025, N = 1,344 patients). IL, interleukin; Mel, melanoma; nsqNSCLC, nonsquamous non-small cell lung cancer; RCC, renal cell carcinoma; sqNSCLC, squamous NSCLC. aIncludes patients who were treated with nivolumab or nivolumab + ipilimumab and had nonmissing serum IL-8 levels.

Back to article page